share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股东委托书决议
美股SEC公告 ·  09/28 05:24

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc. (Adial) has announced the upcoming 2024 Annual Meeting of Stockholders to be held on November 12, 2024. The meeting will address several key proposals, including the election of two Class III directors, the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the number of shares available under the 2017 Equity Incentive Plan from 500,000 to 2,000,000. Additionally, advisory votes will be held on executive compensation and the frequency of future advisory votes on executive compensation. The Board of Directors has fixed September 26, 2024, as the record date for determining stockholders entitled to notice and vote at the meeting. Proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2023, will be mailed to stockholders around October 3, 2024. The Board recommends voting for all the proposals and has provided detailed information regarding the meeting's agenda, executive compensation, and related-party transactions.
Adial Pharmaceuticals, Inc. (Adial) has announced the upcoming 2024 Annual Meeting of Stockholders to be held on November 12, 2024. The meeting will address several key proposals, including the election of two Class III directors, the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the number of shares available under the 2017 Equity Incentive Plan from 500,000 to 2,000,000. Additionally, advisory votes will be held on executive compensation and the frequency of future advisory votes on executive compensation. The Board of Directors has fixed September 26, 2024, as the record date for determining stockholders entitled to notice and vote at the meeting. Proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2023, will be mailed to stockholders around October 3, 2024. The Board recommends voting for all the proposals and has provided detailed information regarding the meeting's agenda, executive compensation, and related-party transactions.
Adial Pharmaceuticals, Inc.（Adial）宣布将在2024年11月12日召开股东年会。会议将讨论几个关键提案，包括选举两名第三类董事，确认Marcum LLP为截至2024年12月31日的财政年度独立注册会计师事务所，批准修正案将2017年股权激励计划下可用股份数量从50万股增加至200万股。此外，还将就执行薪酬和未来关于执行薪酬问题的咨询性投票进行表决。董事会已确定2024年9月26日为股东资格通知和参加会议投票的股东登记日。代理材料，包括截至2023年12月31日的第10-k表格年度报告，将于2024年10月3日左右寄给股东。董事会建议投票支持所有提案，并就会议议程、执行薪酬和关联交易提供了详细信息。
Adial Pharmaceuticals, Inc.（Adial）宣布将在2024年11月12日召开股东年会。会议将讨论几个关键提案，包括选举两名第三类董事，确认Marcum LLP为截至2024年12月31日的财政年度独立注册会计师事务所，批准修正案将2017年股权激励计划下可用股份数量从50万股增加至200万股。此外，还将就执行薪酬和未来关于执行薪酬问题的咨询性投票进行表决。董事会已确定2024年9月26日为股东资格通知和参加会议投票的股东登记日。代理材料，包括截至2023年12月31日的第10-k表格年度报告，将于2024年10月3日左右寄给股东。董事会建议投票支持所有提案，并就会议议程、执行薪酬和关联交易提供了详细信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间